The impact of class III (morbid) obesity on heterotopic ossification outcomes

Waleed Fouad Mourad, Satya Packianathan, Rania A. Shourbaji, Zhen Zhang, Majid A. Khan, Matthew Graves, Michael C. Baird, George Russell, Srinivasan Vijayakumar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Obesity is associated with a chronic low inflammatory process that may act as common soil for the pathogenesis of obesity-related comorbidities including heterotopic ossification (HO). The purpose of this study is to compare the incidence of HO between patients with body mass index (BMI) <40 versus ≥40 after operative treatment of displaced acetabular fractures followed by radiation therapy (RT) ± indomethacin. Methods and Materials: This is a single institution retrospective chart review of 419 patients. All patients with well-documented BMI underwent operative treatment followed by RT ± indomethacin. All patients received 700 cGy to the soft tissues around the proximal femur and acetabulum without bone shielding. All RT were given postoperatively within 72 hours. The patients were divided into 2groups: Group (A) BMI < 40 and Group (B) BMI ≥40. HO was assessed with X-ray. BMI was used as a surrogate measure to test the risk of HO despite prophylaxis. Results: The incidence of HO among all patients is 21% (89 of 419), while among those in group A (BMI <40), 68 of 374 patients developed HO (18%); in the morbidly obese group (BMI ≥40) 21of 45 patients developed HO (47%). The difference between the rates of HO in the 2 groups was 29%; the χ 2 test showed a significant difference between the 2 BMI groups (P < .001 at α = 0.05). Conclusions: There is a higher incidence of HO among the morbidly obese patients despite RT ± indomethacin. RT doses for HO prophylaxis in morbidly obese patients need to be reassessed; also, understanding the signaling pathways in target tissues in obese patients at which adipokines control metabolism may reveal novel therapies. Higher radiation doses ± indomethacin may need to be considered and optimally evaluated in the context of a prospective, randomized clinical trial.

Original languageEnglish (US)
JournalPractical Radiation Oncology
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2012

Fingerprint

Heterotopic Ossification
Morbid Obesity
Body Mass Index
Radiotherapy
Indomethacin
Incidence
Obesity
Acetabulum
Adipokines
Femur
Comorbidity
Soil
Therapeutics
Randomized Controlled Trials

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Mourad, W. F., Packianathan, S., Shourbaji, R. A., Zhang, Z., Khan, M. A., Graves, M., ... Vijayakumar, S. (2012). The impact of class III (morbid) obesity on heterotopic ossification outcomes. Practical Radiation Oncology, 2(3). https://doi.org/10.1016/j.prro.2011.11.003

The impact of class III (morbid) obesity on heterotopic ossification outcomes. / Mourad, Waleed Fouad; Packianathan, Satya; Shourbaji, Rania A.; Zhang, Zhen; Khan, Majid A.; Graves, Matthew; Baird, Michael C.; Russell, George; Vijayakumar, Srinivasan.

In: Practical Radiation Oncology, Vol. 2, No. 3, 01.07.2012.

Research output: Contribution to journalArticle

Mourad, WF, Packianathan, S, Shourbaji, RA, Zhang, Z, Khan, MA, Graves, M, Baird, MC, Russell, G & Vijayakumar, S 2012, 'The impact of class III (morbid) obesity on heterotopic ossification outcomes', Practical Radiation Oncology, vol. 2, no. 3. https://doi.org/10.1016/j.prro.2011.11.003
Mourad, Waleed Fouad ; Packianathan, Satya ; Shourbaji, Rania A. ; Zhang, Zhen ; Khan, Majid A. ; Graves, Matthew ; Baird, Michael C. ; Russell, George ; Vijayakumar, Srinivasan. / The impact of class III (morbid) obesity on heterotopic ossification outcomes. In: Practical Radiation Oncology. 2012 ; Vol. 2, No. 3.
@article{523ff1b3469141fb951ebc8d8ca4d5d5,
title = "The impact of class III (morbid) obesity on heterotopic ossification outcomes",
abstract = "Purpose: Obesity is associated with a chronic low inflammatory process that may act as common soil for the pathogenesis of obesity-related comorbidities including heterotopic ossification (HO). The purpose of this study is to compare the incidence of HO between patients with body mass index (BMI) <40 versus ≥40 after operative treatment of displaced acetabular fractures followed by radiation therapy (RT) ± indomethacin. Methods and Materials: This is a single institution retrospective chart review of 419 patients. All patients with well-documented BMI underwent operative treatment followed by RT ± indomethacin. All patients received 700 cGy to the soft tissues around the proximal femur and acetabulum without bone shielding. All RT were given postoperatively within 72 hours. The patients were divided into 2groups: Group (A) BMI < 40 and Group (B) BMI ≥40. HO was assessed with X-ray. BMI was used as a surrogate measure to test the risk of HO despite prophylaxis. Results: The incidence of HO among all patients is 21{\%} (89 of 419), while among those in group A (BMI <40), 68 of 374 patients developed HO (18{\%}); in the morbidly obese group (BMI ≥40) 21of 45 patients developed HO (47{\%}). The difference between the rates of HO in the 2 groups was 29{\%}; the χ 2 test showed a significant difference between the 2 BMI groups (P < .001 at α = 0.05). Conclusions: There is a higher incidence of HO among the morbidly obese patients despite RT ± indomethacin. RT doses for HO prophylaxis in morbidly obese patients need to be reassessed; also, understanding the signaling pathways in target tissues in obese patients at which adipokines control metabolism may reveal novel therapies. Higher radiation doses ± indomethacin may need to be considered and optimally evaluated in the context of a prospective, randomized clinical trial.",
author = "Mourad, {Waleed Fouad} and Satya Packianathan and Shourbaji, {Rania A.} and Zhen Zhang and Khan, {Majid A.} and Matthew Graves and Baird, {Michael C.} and George Russell and Srinivasan Vijayakumar",
year = "2012",
month = "7",
day = "1",
doi = "10.1016/j.prro.2011.11.003",
language = "English (US)",
volume = "2",
journal = "Practical Radiation Oncology",
issn = "1879-8500",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - The impact of class III (morbid) obesity on heterotopic ossification outcomes

AU - Mourad, Waleed Fouad

AU - Packianathan, Satya

AU - Shourbaji, Rania A.

AU - Zhang, Zhen

AU - Khan, Majid A.

AU - Graves, Matthew

AU - Baird, Michael C.

AU - Russell, George

AU - Vijayakumar, Srinivasan

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Purpose: Obesity is associated with a chronic low inflammatory process that may act as common soil for the pathogenesis of obesity-related comorbidities including heterotopic ossification (HO). The purpose of this study is to compare the incidence of HO between patients with body mass index (BMI) <40 versus ≥40 after operative treatment of displaced acetabular fractures followed by radiation therapy (RT) ± indomethacin. Methods and Materials: This is a single institution retrospective chart review of 419 patients. All patients with well-documented BMI underwent operative treatment followed by RT ± indomethacin. All patients received 700 cGy to the soft tissues around the proximal femur and acetabulum without bone shielding. All RT were given postoperatively within 72 hours. The patients were divided into 2groups: Group (A) BMI < 40 and Group (B) BMI ≥40. HO was assessed with X-ray. BMI was used as a surrogate measure to test the risk of HO despite prophylaxis. Results: The incidence of HO among all patients is 21% (89 of 419), while among those in group A (BMI <40), 68 of 374 patients developed HO (18%); in the morbidly obese group (BMI ≥40) 21of 45 patients developed HO (47%). The difference between the rates of HO in the 2 groups was 29%; the χ 2 test showed a significant difference between the 2 BMI groups (P < .001 at α = 0.05). Conclusions: There is a higher incidence of HO among the morbidly obese patients despite RT ± indomethacin. RT doses for HO prophylaxis in morbidly obese patients need to be reassessed; also, understanding the signaling pathways in target tissues in obese patients at which adipokines control metabolism may reveal novel therapies. Higher radiation doses ± indomethacin may need to be considered and optimally evaluated in the context of a prospective, randomized clinical trial.

AB - Purpose: Obesity is associated with a chronic low inflammatory process that may act as common soil for the pathogenesis of obesity-related comorbidities including heterotopic ossification (HO). The purpose of this study is to compare the incidence of HO between patients with body mass index (BMI) <40 versus ≥40 after operative treatment of displaced acetabular fractures followed by radiation therapy (RT) ± indomethacin. Methods and Materials: This is a single institution retrospective chart review of 419 patients. All patients with well-documented BMI underwent operative treatment followed by RT ± indomethacin. All patients received 700 cGy to the soft tissues around the proximal femur and acetabulum without bone shielding. All RT were given postoperatively within 72 hours. The patients were divided into 2groups: Group (A) BMI < 40 and Group (B) BMI ≥40. HO was assessed with X-ray. BMI was used as a surrogate measure to test the risk of HO despite prophylaxis. Results: The incidence of HO among all patients is 21% (89 of 419), while among those in group A (BMI <40), 68 of 374 patients developed HO (18%); in the morbidly obese group (BMI ≥40) 21of 45 patients developed HO (47%). The difference between the rates of HO in the 2 groups was 29%; the χ 2 test showed a significant difference between the 2 BMI groups (P < .001 at α = 0.05). Conclusions: There is a higher incidence of HO among the morbidly obese patients despite RT ± indomethacin. RT doses for HO prophylaxis in morbidly obese patients need to be reassessed; also, understanding the signaling pathways in target tissues in obese patients at which adipokines control metabolism may reveal novel therapies. Higher radiation doses ± indomethacin may need to be considered and optimally evaluated in the context of a prospective, randomized clinical trial.

UR - http://www.scopus.com/inward/record.url?scp=84862637124&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862637124&partnerID=8YFLogxK

U2 - 10.1016/j.prro.2011.11.003

DO - 10.1016/j.prro.2011.11.003

M3 - Article

AN - SCOPUS:84862637124

VL - 2

JO - Practical Radiation Oncology

JF - Practical Radiation Oncology

SN - 1879-8500

IS - 3

ER -